Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
  • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/32—Alcohol-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to the use of CDP-choline for the treatment of alcohol withdrawal syndrome.
• Histological alterations of neuronal structure consist in a lesser branching of hippocampus nerve cells and Purkinje's cells. Comparison of brains from healthy subjects with those from alcoholic patients revealed a lesser branching of pyramidal neuronal basal dendrites in upper cerebral cortex and motor cortex (Ledig M. and Mandel P., M S-
• CDP-choline cytidine diphosphate choline, Citicoline
• CDP-choline is a key intermediate in the synthesis of structural phospholipids present in the neuronal membrane (Kennedy E. P. and Weiss S. B., J " . Biol . Chem. , 1956; 222, 193-214) and plays an important role in its formation and repair when the phospholipidic structure is damaged by endogenous or exogenous causes involving a decrease in cytidine and choline uptake.
• CDP-choline enhances dopamine synthesis and release (Martinet M. et al . , Biochem.
• CDP-choline administered to alcoholic patients reduces the duration and intensity of their withdrawal symtoms and induces an evident recovery in a significant proportion of patients .
• CDP-choline which includes a method for treating alcohol withdrawal syndrome, comprises the administration of an effective amount of CDP-choline or a pharmaceutically acceptable salt thereof to an alcoholic patient.
• CDP-choline is administered as free compound or as a pharmaceutically acceptable salt, whether in anhydrous or hydrated form, conveniently mixed with pharmaceutical carriers and/or excipients, to humans at daily doses of 0.5 to 2 g inclusive in free CDP-choline, preferably from 0.5 to 1 g inclusive, both orally and parentally.
• compositions of CDP-choline include its alkaline or alkaline earth salts, such as its sodium, potassium, calcium and magnesium salts or its acid addition salts with a mineral or organic acid, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, citric acid, lactic acid, malonic acid, tartaric acid, acrylic acid, metacrylic acid, malic acid, maleic acid, fumaric acid, benzoic acid, salicylic acid, cinnamic acid, methane sulphonic acid, benzenesulphonic acid, p-toluensulphonic acid and nicotinic acid.
• a mineral or organic acid such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, citric acid, lactic acid, malonic acid, tartaric acid, acrylic acid, metacrylic acid, malic acid,
• CDP-choline and its salts may be administered orally in the form of tablets, capsules, powder, granules, cachets, lozenges, solution, suspension, emulsion, syrup, gel and the like; or parenterally in the form of solution, suspension, emulsion or the like for intravenous or intramuscular injection.
• CDP-choline sodium salt 522.5 mg
• CDP-choline, sodium salt 26.12 g
• Disodium citrate 0.60 g
• CDP-choline sodium salt 522.50 mg
• CDP-choline was administered at doses of 500 mg/d i.m. or 600 mg/d p.o. for 60 days. At 30 and 60 days following treatment, significant differences (p ⁇ 0.001) were observed in the assessments performed. At 60 days, 55.83% of patients had given up drinking alcohol and 31.97% of patients drank much less. A significant improvement was observed on anxiety, tremor, disorientation, insomnia, dysarthria, tendency to suicide and neuritic pains.
• EXAMPLE 5 Open, randomized, comparative clinical study of CDP-choline in alcohol withdrawal syndrome versus clomethiazole and vitamin B.
• the patients who received CDP-choline plus the conventional therapy showed significant differences versus control at 30 days following treatment in tremor incidence (p ⁇ 0.05), cramps (p ⁇ 0.05), asthenia (p ⁇ 0.05), emotional lability (p ⁇ 0.01), nervousness (p ⁇ 0.05) and social withdrawal (p ⁇ 0.05).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Addiction (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Molecular Biology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Psychiatry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Saccharide Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (17)

Applications Claiming Priority (2)

Publications (2)

Family

ID=8492914

Family Applications (1)

Country Status (21)

Cited By (6)

Families Citing this family (1)

Family Cites Families (8)

• 2000
  • 2000-03-29 ES ES200000765A patent/ES2170649B1/es not_active Expired - Fee Related
• 2001
  • 2001-03-28 JP JP2001570249A patent/JP4724348B2/ja not_active Expired - Fee Related
  • 2001-03-28 CA CA002402707A patent/CA2402707C/en not_active Expired - Fee Related
  • 2001-03-28 NZ NZ520825A patent/NZ520825A/en not_active IP Right Cessation
  • 2001-03-28 IL IL15116301A patent/IL151163A0/xx active IP Right Grant
  • 2001-03-28 DK DK01936147T patent/DK1267892T3/da active
  • 2001-03-28 AT AT01936147T patent/ATE281172T1/de active
  • 2001-03-28 RU RU2002129579/15A patent/RU2251422C2/ru not_active IP Right Cessation
  • 2001-03-28 PT PT01936147T patent/PT1267892E/pt unknown
  • 2001-03-28 BR BR0109477-7A patent/BR0109477A/pt not_active Application Discontinuation
  • 2001-03-28 US US10/240,159 patent/US6894032B2/en not_active Expired - Lifetime
  • 2001-03-28 PL PL363177A patent/PL199291B1/pl unknown
  • 2001-03-28 MX MXPA02009442A patent/MXPA02009442A/es active IP Right Grant
  • 2001-03-28 CZ CZ20023245A patent/CZ298933B6/cs not_active IP Right Cessation
  • 2001-03-28 KR KR1020027012966A patent/KR100794891B1/ko not_active Expired - Fee Related
  • 2001-03-28 AU AU2001262141A patent/AU2001262141B2/en not_active Ceased
  • 2001-03-28 AU AU6214101A patent/AU6214101A/xx active Pending
  • 2001-03-28 WO PCT/EP2001/003536 patent/WO2001072288A2/en not_active Ceased
  • 2001-03-28 EP EP01936147A patent/EP1267892B1/en not_active Expired - Lifetime
  • 2001-03-28 DE DE60106890T patent/DE60106890T2/de not_active Expired - Lifetime
• 2002
  • 2002-08-08 ZA ZA200206349A patent/ZA200206349B/en unknown
  • 2002-08-09 IL IL151163A patent/IL151163A/en not_active IP Right Cessation
  • 2002-09-24 NO NO20024574A patent/NO329766B1/no not_active IP Right Cessation

Also Published As

Similar Documents

Legal Events